Biological false positive serological tests for syphilis in the Jamaican population

M F Smikle, O B'L James, P Prabhakar

Abstract
A total of 19,067 sera were screened for biological false positive (BFP) reactivity by the Venereal Disease Research Laboratory (VDRL) test. Sera which were reactive in the VDRL test were confirmed by the fluorescent treponemal antibody absorption (FTA-ABS) test. BFP reactions were detected in 0.59% of the general population, 0.72% of pregnant women and 11.8% of patients with systemic lupus erythematosus (SLE). The rate of BFP reactors among pregnant women did not differ significantly from the general population. The female to male ratio of BFP in the general population was 2:1 whilst that in the group of patients with SLE was 8:1. The overall seroprevalence of syphilis was 2.2%.

The best standardised and most widely used non-treponemal, screening test for syphilis is the Venereal Disease Research Laboratory (VDRL) test. By virtue of the non-specificity of antigen (a mixture of cardiolipin, cholesterol and lecithin) the VDRL may yield “biological false positive” (BFP) results. A BFP test for syphilis is considered to be a reactive non-treponemal test but a nonreactive treponemal test. BFP tests have been further categorized as “acute” or “chronic”. Acute BFP tests disappear within six months and have been reported in pregnancy, drug addiction, following acute infectious diseases and in healthy persons. Chronic BFP tests remain beyond six months sometimes indefinitely and have been reported in rheumatic disorders, dermatological diseases, chronic infectious diseases and healthy persons. The BFP results encountered in routine screening of the general population are often difficult or impossible to explain and may provide cause for worry or embarrassment to patients. Of even greater importance, a BFP may be the harbinger of an underlying serious disorder. BFP reactors may be given penicillin repeatedly on the assumption that they have syphilis.

The Treponema pallidum Haemagglutination Assay (TPHA) is the most widely used specific test for syphilis. Use of this test reduces the number of inadequately treated persons who are positive in routine screening for syphilis, as the test usually becomes negative within one to two years in patients who are treated during the primary or early secondary stages of syphilis. On the other hand, the TPHA is less sensitive than the VDRL in the early primary stage of syphilis and is the most sensitive test for latent syphilis. The Fluorescent Treponemal Antibody Absorption (FTA-ABS) test may be used to confirm the results of both these tests.

In this laboratory the FTA-ABS test and VDRL are used to confirm the diagnosis of syphilis. Positive treponemal tests in Jamaicans under 40 years of age are considered to be due to syphilis as yaws was eradicated from the island in 1960. Confirmatory tests for syphilis are available only at the two major urban Jamaican hospitals. The tendency therefore, is to treat all persons, including pregnant women, for syphilis on the basis of the VDRL test alone. In addition rheumatic disorders are fairly common in Jamaica.

The prevalence of BFP VDRL tests in the general population should be established before the level of association with any clinical entity can be accurately assessed. It would also be interesting to assess the clinical accuracy of physicians who do not rely on confirmatory tests in populations such as ours.

In this paper, we report the prevalence of BFP tests in the general Jamaican population, in pregnancy and in cases of systemic lupus erythematosus (SLE).

Patients and methods
Standard VDRL tests were performed on sera from 15,876 members of the general adult emigrant population, 3039 women attending antenatal clinics throughout the island and 152 patients with systemic lupus erythematosus (SLE).

Sera from SLE patients which were reactive in the VDRL test and sera from the general population and pregnant women which reacted at titres less than 1:8 were further tested by the Fluorescent Treponemal Antibody Absorption (FTA-ABS) test.
STATISTICAL ANALYSIS
The Chi-square test was used for data comparisons.

Results
Of the 15,876 (2.8%) specimens from the general public, 441 were VDRL positive. Of these, 94 (21.3%) had titres greater than 1:4. In pregnant women, 145 out of 3039 (4.7%) sera were reactive, of which, 70 (48.2%) had titres greater than 1:4. (Titres ranged from 1:8 to 1:128.)

Sera from 94 (27.1%) of the general adult population that were VDRL positive and 22 (30.9%) of pregnant women with a positive VDRL gave reactive titres of less than 1:8 while being non-reactive by the FTA-ABS test. On the other hand, 18 (78.2%) of VDRL reactive sera from SLE patients gave non-reactive FTA-ABS results. These results are shown in the table. One serum from a patient with SLE had a VDRL titre of 1:128, but was non-reactive in the FTA-ABS test.

There was no statistically significant difference between the prevalence of BFP in the general population and that in pregnant women. The prevalence of BFP in SLE patients (11.8%) was statistically higher than the general population (94/15876, 0.59%, p < 0.001) as well as pregnant women (22/3039, 0.72%, p < 0.001). The overall seroprevalence of syphilis was 2.2%.

Discussion
Although 0.9% of persons in the study had VDRL titres greater than 1:4 and as high as 1:128, none of these persons had clinical manifestations of syphilis at presentation. None had a history of yaws; therefore, all were presumed to be cases of treated or latent syphilis.

The results of this study emphasise the need to perform confirmatory tests for syphilis in the Jamaican population. Thus, 27.1% in the general population and 30.9% in pregnant women of low-titred VDRL reactive sera were BFP. Seventy-eight per cent of reactive VDRL tests in SLE patients were BFP. None of these patients had history or clinical evidence of treponemal disease. The finding of a BFP VDRL test with a titre of 1:128 in a patient with SLE is unusual.7,16

The overall prevalence of BFP VDRL tests in the general population 0.59% and pregnant women (0.72%) was relatively low and was in keeping with previous studies of unselected populations.6,17 It was interesting that the prevalence of BFP test was not statistically significantly different when pregnant women and members of the general population were compared. Other authors have stated that pregnancy is a cause of BFP results.2 Our results do not support this view but rather that of Catteral, who suggests that although many BFP tests are detected during pregnancy, this condition may or may not be the cause of BFP test.7

A BFP VDRL test is one of the American Rheumatism Associations (ARA) criteria for diagnosis of SLE.18 We observed a high prevalence of BFP in our SLE group (11.8%), similar to that found in other studies.19,20 In our series, a BFP test was not associated with any given clinical manifestation in patients with SLE, yet such associations with anticardiolipin antibodies have been reported.21

Since all patients with SLE had a BFP test for more than six months duration, the chronicity of the BFP test was established. Unfortunately, in the general population the BFP VDRL test was not categorised as acute or chronic as these were cases of routine screening for emigration purposes. Acute BFP tests are usually of no significance but chronic tests are associated with several systemic diseases, including malignancies. Chronic BFP tests have been shown to be more frequent and to have more serious implications in women than men as the associated autoimmune diseases tend to be more prevalent in women.4,18 The female to male ratio of BFP tests in our general population group was 2:1 whilst in the SLE group it was 8:1. In pregnant women, every effort should be made to categorise BFP tests as acute or chronic, rather than presume that they are caused by pregnancy.

From this study, we recommend that regardless of titre, confirmatory tests should be performed on all sera with a positive VDRL. All BFP reactors should be followed up and categorised as acute or chronic. Those with chronic BFP results should be investigated for clinical and laboratory indicators of autoimmune or other chronic diseases. These measures would reduce the indiscriminate and inappropriate use of antibiotics. This is of particular importance to patients with autoimmune diseases as there is a greater frequency of penicillin and other hypersensitivity drug reactions in this group. The situation is further complicated by the fact that administration of penicillin has been associated with the onset of symptoms of autoimmune disease.7

In summary, confirmatory tests for syphilis should be performed on all Jamaican patients with low titre

<table>
<thead>
<tr>
<th>Table</th>
<th>Confirmation of reactive VDRL by FTA-ABS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Group (n)</td>
<td>Overall Reactive VDRL (%)</td>
</tr>
<tr>
<td>General population (441)</td>
<td>2(7)</td>
</tr>
<tr>
<td>(15876)</td>
<td></td>
</tr>
<tr>
<td>Pregnant women (3039)</td>
<td>145 (4.7)</td>
</tr>
<tr>
<td>Systemic lupus erythematosus (152)</td>
<td>23 (4)</td>
</tr>
</tbody>
</table>

*VDRL titres less than 1:8.
VDRL reactivity, mindful of the relatively high prevalence of conditions associated with BFP reactions.

We thank the Technical Staff, Immunology Section, Dr Shoucair, Medical Assessment, Jamaica, Dr F. Brathwaite, Ministry of Health; and Mrs E. Pessoa and Miss C. Earle for secretarial assistance.

Address for correspondence: M F Smikle, Department of Microbiology, UWI, Mona, Kingston 7, Jamaica


Accepted for publication 24 November 1989.

Smikle, James, Prabhakar
Biological false positive serological tests for syphilis in the Jamaican population.

M F Smikle, O B James and P Prabhakar

Genitourin Med 1990 66: 76-78
doi: 10.1136/sti.66.2.76

Updated information and services can be found at:
http://sti.bmj.com/content/66/2/76

These include:

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/